• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study
【24h】

Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study

机译：脱氢硫代酮酮补充剂可能使患有低雄激素水平的哮喘的妇女：试点研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionAmong individuals with severe asthma, FEVsub1/sub is low in individuals with low dehydroepiandrosterone (DHEA) sulfate (DHEAS) levels. In the Severe Asthma Research Program (SARP), no women with DHEAS??200?μg/dL had an FEVsub1/sub?1/sub in asthmatic women with low DHEAS. MethodsPremenopausal, nonsmoking, otherwise healthy women, 18-50 years old, with mild or moderate asthma and baseline FEVsub1/sub??60% predicted received 100?mg DHEA orally every 12?h for 2?weeks. Spirometry and DHEAS were measured at the initial visit and 2 weeks later, after completion of DHEA treatment. Based on our previous work, the primary outcome variable for this pilot study was post-albuterol spirometry in the low-DHEAS group. Subjects also continued their other routine asthma management. ResultsSerum DHEAS increased with DHEA treatment in women with starting DHEAS?1/sub increased by 51?mL, from 3.026?±?0.5 to 3.077?±?0.49 L ( n =?10; p =?0.034 by paired t test, significant after Bonferroni), in women with low DHEAS. In the high-DHEAS group (baseline DHEAS?≥?200?μg/dl), post-albuterol FEVsub1/sub did not change significantly ( n =?3, p =?NS). Three subjects were excluded: one had comorbid COPD, one could not perform spirometry, and one did not take the DHEA. There were no adverse effects of DHEA treatment in this trial. ConclusionsEndocrine treatments (corticosteroids) are a mainstay of anti-inflammatory management for moderate and severe asthma. Their use has improved asthma outcomes. Androgens also reduce airway inflammation and promote airway smooth muscle relaxation, but are rarely used clinically?for asthma treatment. Our results suggest that the over-the-counter steroid DHEA may improve lung function in asthma outcomes among women with DHEAS.
机译：引入具有严重哮喘的介绍，FEV 1 在具有低脱氢硫酸酯（DHEA）硫酸盐（DHEAS）水平的个体中较低。在严重的哮喘研究计划（SARP）中，没有DHEAS的女性？> 200？μg/ dL在哮喘妇女中具有低DHEAS的FEV 1 1 。方法富含备注，非镜头，否则健康的女性，18-50岁，哮喘和基线FEV 1 ？> 60％预测每12？H 2？H持续每12？ 。在完成DHEA治疗后，在初始访问和2周后测量肺活量和DHEAS。基于我们以前的工作，该试点研究的主要结果变量是低DHEAS组后的氨基甲甾醇肺活量测定。受试者还继续他们的其他常规哮喘管理。康乳蛋白DHEAS随着DHEAS的妇女的DHEA治疗而增加，从3.026α增加了51？±0.5至3.077？±0.49L（n =？10; P = 0.034通过配对T试验Bonferroni之后，在低DHEAS的女性中显着。在高DHEAS组（基线DHEAS？≥？200？μg/ dl）中，后羟基醇FEV 1 没有显着变化（n =？3，p =？ns）。被排除了三个科目：一个人有康复COPD，一个人无法进行肺活量测定，一个人没有服用DHEA。 DHEA治疗在该试验中没有不良影响。结论分析分析（皮质类固醇）是中度和严重哮喘的抗炎管理的主要抗炎管理。他们的使用改善了哮喘结果。雄激素还减少了气道炎症，促进气道平滑肌松弛，但很少临床使用？哮喘治疗。我们的研究结果表明，反柜台上的类固醇DHEA可以改善DHEAS女性哮喘结果中的肺功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号